Cargando…

Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity

SARS-CoV-2 spike (S) protein mediates virus attachment to the cells and fusion between viral and cell membranes. Membrane fusion is driven by mutual interaction between the highly conserved heptad-repeat regions 1 and 2 (HR1 and HR2) of the S2 subunit of the spike. For this reason, these S2 regions...

Descripción completa

Detalles Bibliográficos
Autores principales: Cano-Muñoz, Mario, Polo-Megías, Daniel, Cámara-Artigas, Ana, Gavira, José A., López-Rodríguez, María J., Laumond, Géraldine, Schmidt, Sylvie, Demiselle, Julien, Bahram, Seiamak, Moog, Christiane, Conejero-Lara, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546781/
https://www.ncbi.nlm.nih.gov/pubmed/36220405
http://dx.doi.org/10.1016/j.ijbiomac.2022.10.031
_version_ 1784805120201981952
author Cano-Muñoz, Mario
Polo-Megías, Daniel
Cámara-Artigas, Ana
Gavira, José A.
López-Rodríguez, María J.
Laumond, Géraldine
Schmidt, Sylvie
Demiselle, Julien
Bahram, Seiamak
Moog, Christiane
Conejero-Lara, Francisco
author_facet Cano-Muñoz, Mario
Polo-Megías, Daniel
Cámara-Artigas, Ana
Gavira, José A.
López-Rodríguez, María J.
Laumond, Géraldine
Schmidt, Sylvie
Demiselle, Julien
Bahram, Seiamak
Moog, Christiane
Conejero-Lara, Francisco
author_sort Cano-Muñoz, Mario
collection PubMed
description SARS-CoV-2 spike (S) protein mediates virus attachment to the cells and fusion between viral and cell membranes. Membrane fusion is driven by mutual interaction between the highly conserved heptad-repeat regions 1 and 2 (HR1 and HR2) of the S2 subunit of the spike. For this reason, these S2 regions are interesting therapeutic targets for COVID-19. Although HR1 and HR2 have been described as transiently exposed during the fusion process, no significant antibody responses against these S2 regions have been reported. Here we designed chimeric proteins that imitate highly stable HR1 helical trimers and strongly bind to HR2. The proteins have broad inhibitory activity against WT B.1 and BA.1 viruses. Sera from COVID-19 convalescent donors showed significant levels of reactive antibodies (IgG and IgA) against the HR1 mimetic proteins, whereas these antibody responses were absent in sera from uninfected donors. Moreover, both inhibitory activity and antigenicity of the proteins correlate positively with their structural stability but not with the number of amino acid changes in their HR1 sequences, indicating a conformational and conserved nature of the involved epitopes. Our results reveal previously undetected spike epitopes that may guide the design of new robust COVID-19 vaccines and therapies.
format Online
Article
Text
id pubmed-9546781
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-95467812022-10-11 Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity Cano-Muñoz, Mario Polo-Megías, Daniel Cámara-Artigas, Ana Gavira, José A. López-Rodríguez, María J. Laumond, Géraldine Schmidt, Sylvie Demiselle, Julien Bahram, Seiamak Moog, Christiane Conejero-Lara, Francisco Int J Biol Macromol Article SARS-CoV-2 spike (S) protein mediates virus attachment to the cells and fusion between viral and cell membranes. Membrane fusion is driven by mutual interaction between the highly conserved heptad-repeat regions 1 and 2 (HR1 and HR2) of the S2 subunit of the spike. For this reason, these S2 regions are interesting therapeutic targets for COVID-19. Although HR1 and HR2 have been described as transiently exposed during the fusion process, no significant antibody responses against these S2 regions have been reported. Here we designed chimeric proteins that imitate highly stable HR1 helical trimers and strongly bind to HR2. The proteins have broad inhibitory activity against WT B.1 and BA.1 viruses. Sera from COVID-19 convalescent donors showed significant levels of reactive antibodies (IgG and IgA) against the HR1 mimetic proteins, whereas these antibody responses were absent in sera from uninfected donors. Moreover, both inhibitory activity and antigenicity of the proteins correlate positively with their structural stability but not with the number of amino acid changes in their HR1 sequences, indicating a conformational and conserved nature of the involved epitopes. Our results reveal previously undetected spike epitopes that may guide the design of new robust COVID-19 vaccines and therapies. The Authors. Published by Elsevier B.V. 2022-12-01 2022-10-08 /pmc/articles/PMC9546781/ /pubmed/36220405 http://dx.doi.org/10.1016/j.ijbiomac.2022.10.031 Text en © 2023 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Cano-Muñoz, Mario
Polo-Megías, Daniel
Cámara-Artigas, Ana
Gavira, José A.
López-Rodríguez, María J.
Laumond, Géraldine
Schmidt, Sylvie
Demiselle, Julien
Bahram, Seiamak
Moog, Christiane
Conejero-Lara, Francisco
Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity
title Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity
title_full Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity
title_fullStr Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity
title_full_unstemmed Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity
title_short Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity
title_sort novel chimeric proteins mimicking sars-cov-2 spike epitopes with broad inhibitory activity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546781/
https://www.ncbi.nlm.nih.gov/pubmed/36220405
http://dx.doi.org/10.1016/j.ijbiomac.2022.10.031
work_keys_str_mv AT canomunozmario novelchimericproteinsmimickingsarscov2spikeepitopeswithbroadinhibitoryactivity
AT polomegiasdaniel novelchimericproteinsmimickingsarscov2spikeepitopeswithbroadinhibitoryactivity
AT camaraartigasana novelchimericproteinsmimickingsarscov2spikeepitopeswithbroadinhibitoryactivity
AT gavirajosea novelchimericproteinsmimickingsarscov2spikeepitopeswithbroadinhibitoryactivity
AT lopezrodriguezmariaj novelchimericproteinsmimickingsarscov2spikeepitopeswithbroadinhibitoryactivity
AT laumondgeraldine novelchimericproteinsmimickingsarscov2spikeepitopeswithbroadinhibitoryactivity
AT schmidtsylvie novelchimericproteinsmimickingsarscov2spikeepitopeswithbroadinhibitoryactivity
AT demisellejulien novelchimericproteinsmimickingsarscov2spikeepitopeswithbroadinhibitoryactivity
AT bahramseiamak novelchimericproteinsmimickingsarscov2spikeepitopeswithbroadinhibitoryactivity
AT moogchristiane novelchimericproteinsmimickingsarscov2spikeepitopeswithbroadinhibitoryactivity
AT conejerolarafrancisco novelchimericproteinsmimickingsarscov2spikeepitopeswithbroadinhibitoryactivity